Cutaneous tissue repair involves an initial inflammatory phase, followed by a fibroproliferative phase and finally by a resolution phase. Failure to initiate fibroblast recruitment during the fibroproliferative phase results in chronic wounds, whereas failure to terminate the fibroproliferative phase results in fibroproliferative disorders. Thus, understanding how to regulate the fibroproliferative phase of tissue repair is, therefore, of high clinical relevance. Controlling the rate of the fibroproliferative response is essential to promote proper wound repair.
Recent Advances:
(1) The myofibroblast is essential for mediating the fibroproliferative phase of tissue repair. (2) The potent profibrotic cytokine transforming growth factor beta (TGF-β) is a major in vivo contributor to myofibroblast differentiation and activity in vivo.
Critical Issues:
An increasing body of evidence indicates that the transcription factor peroxisome proliferator–activated receptor gamma (PPAR-γ) plays a key in vivo role in suppressing the fibrogenic response by antagonizing TGF-β signaling. Excessive scarring and/or chronic wounds, caused by a dysregulated fibroproliferative phase, are major clinical problems in response to tissue injury.
Future Directions:
The development of drugs to control the rate of the fibroproliferative response are clinically relevant. Controlling PPAR-γ activity may be useful for prevention of scarring as well as for promoting the closure of chronic wounds.
Get full access to this article
View all access options for this article.
References
1.
HinzB, PhanSH, ThannickalVJ, PrunottoM, DesmoulièreA, VargaJ, De WeverO, MareelM, GabbianiG. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol, 2012; 180:1340.
2.
DesmoulièreA, ChaponnierC, GabbianiG. Tissue repair, contraction, and the myofibroblast. Wound Repair Regen, 2005; 13:7.
3.
LeaskA. Possible strategies for anti-fibrotic drug intervention in scleroderma. J Cell Commun Signal, 2011; 5:125.
4.
VerrecchiaF, MauvielA. Transforming growth factor-beta and fibrosis. World J Gastroenterol, 2007; 13:3056.
5.
GhoshAK, VargaJ. The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. J Cell Physiol, 2007; 213:663.
6.
WeiJ, BhattacharyyaS, VargaJ. Peroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis. Curr Opin Rheumatol, 2010; 22:671.
7.
YangJ, ZhouY, GuanY. PPARγ as a therapeutic target in diabetic nephropathy and other renal diseases. Curr Opin Nephrol Hypertens, 2012; 21:97.
8.
KapoorM, KojimaF, YangL, CroffordLJ. Sequential induction of pro-, anti-inflammatory prostaglandins, peroxisome proliferators-activated receptor-gamma during normal wound healing: a time course study. Prostaglandins Leukot Essent Fatty Acids, 2007; 76:103.
9.
CollinoM, PatelNS, ThiemermannC. PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury. Ther Adv Cardiovasc Dis, 2008; 2:179.
10.
KapadiaR, YiJH, VemugantiR. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci, 2008; 13:1813.
11.
VillacortaL, SchopferFJ, ZhangJ, FreemanBA, ChenYE. PPARgamma and its ligands: therapeutic implications in cardiovascular disease. Clin Sci (Lond), 2009; 116:205.
12.
LeahyJL. Thiazolidinediones in prediabetes and early type 2 diabetes: what can be learned about that disease's pathogenesis. Curr Diab Rep, 2009; 9:215.
13.
TakagawaS, LakosG, MoriY, YamamotoT, NishiokaK, VargaJ. Sustained activation of fibroblast transforming growth factor-beta/Smad signaling in a murine model of scleroderma. J Invest Dermatol, 2003; 121:41.
14.
CutroneoKR, PhanSH. TGF-beta1-induced Smad 3 binding to the Smad 7 gene: knockout of Smad 7 gene transcription by sense phosphorothioate oligos, autoregulation, and effect on TGF-beta1 secretion: bleomycin acts through TGF-beta1. J Cell Biochem, 2003; 89:474.
15.
LeaskA, AbrahamDJ. TGF-beta signaling and the fibrotic response. FASEB J, 2004; 18:816.
FlandersKC, SullivanCD, FujiiM, SowersA, AnzanoMA, ArabshahiA, MajorC, DengC, RussoA, MitchellJB, RobertsAB. Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am J Pathol, 2002; 160:1057.
18.
LakosG, TakagawaS, ChenSJ, FerreiraAM, HanG, MasudaK, WangXJ, DiPietroLA, VargaJ. Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol, 2004; 165:203.
19.
GhoshAK, BhattacharyyaS, LakosG, ChenSJ, MoriY, VargaJ. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum, 2004; 50:1305.
20.
BurgessHA, DaughertyLE, ThatcherTH, LakatosHF, RayDM, RedonnetM, PhippsRP, SimePJ. PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol, 2005; 288:L1146
21.
ZhangGY, ChengT, ZhengMH, YiCG, PanH, LiZJ, ChenXL, YuQ, JiangLF, ZhouFY, LiXY, YangJQ, ChuTG, GaoWY. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist inhibits transforming growth factor-beta1 and matrix production in human dermal fibroblasts. J Plast Reconstr Aesthet Surg, 2010; 63:1209.
22.
WuM, MelichianDS, ChangE, Warner-BlankenshipM, GhoshAK, VargaJ. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol, 2009; 174:519.
FergusonHE, KulkarniA, LehmannGM, Garcia-BatesTM, ThatcherTH, HuxlinKR, PhippsRP, SimePJ. Electrophilic peroxisome proliferator-activated receptor-gamma ligands have potent antifibrotic effects in human lung fibroblasts. Am J Respir Cell Mol Biol, 2009; 41:722.
29.
MughalRS, WarburtonP, O'ReganDJ, BallSG, TurnerNA, PorterKE. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function. Clin Exp Pharmacol Physiol, 2009; 36:478.
30.
AmatoAA, de Assis Rocha NevesF. Idealized PPARγ-based therapies: lessons from bench and bedside. PPAR Res, 2012; 2012:978687.
31.
FiévetC, FruchartJC, StaelsB. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol, 2006; 6:606.
32.
SaikaS, YamanakaO, OkadaY, MiyamotoT, KitanoA, FlandersKC, OhnishiY, NakajimaY, KaoWW, IkedaK. Effect of over expression of PPARgamma on the healing process of corneal alkali burn in mice. Am J Physiol Cell Physiol, 2007; 293:C75.
